We are live on ! Find out more
MBVX

MABVAX THERAPEUTICS HLDGS INC
MBVX

Delisted

MBVX was delisted on the 10th of July, 2018.

Back to rankings

7 hedge funds and large institutions have $405K invested in MABVAX THERAPEUTICS HLDGS INC in 2016 Q3 according to their latest regulatory filings, with 7 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
7
Holders Change
+7
Holders Change %
–
% of All Funds
0.19%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
7
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VKH
Virtu KCG Holdings
New York
+$344K
2
BCM
Biomark Capital Management
Connecticut
+$134K
3
TRCT
Tower Research Capital (TRC)
New York
+$1.66K
4
UBS Group
UBS Group
Switzerland
+$678
5
TCM
Tradewinds Capital Management
Washington
+$542

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
VKH
1
Virtu KCG Holdings
New York
$290K +$344K +22,822 New
BCM
2
Biomark Capital Management
Connecticut
$113K +$134K +8,903 New
UBS Group
3
UBS Group
Switzerland
$1K +$678 +45 New
TRCT
4
Tower Research Capital (TRC)
New York
$1K +$1.66K +110 New
Deutsche Bank
5
Deutsche Bank
Germany
– +$15 +1 New
LTFS
6
Ladenburg Thalmann Financial Services
Florida
– +$30 +2 New
TCM
7
Tradewinds Capital Management
Washington
– +$542 +36 New

MBVX Hedge Fund Activity: Q3 2016 in Review

7 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in MABVAX THERAPEUTICS HLDGS INC (MBVX) for Q3 2016, worth a combined $405K.

Buyers outnumbered sellers: 7 funds opened new MBVX positions and 0 closed out — a net gain of 7 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Virtu KCG Holdings, opening a new position worth an estimated $344K.

  • 7 institutional investors held MABVAX THERAPEUTICS HLDGS INC (MBVX) as of Q3 2016, up from 0 in Q2 2016.
  • Funds reported $405K of MABVAX THERAPEUTICS HLDGS INC stock for Q3 2016.
  • 7 funds opened new MABVAX THERAPEUTICS HLDGS INC positions in Q3 2016 and 0 closed out, a net change of +7 holders.
  • The largest MABVAX THERAPEUTICS HLDGS INC buyer in Q3 2016 was Virtu KCG Holdings, an estimated $344K added.

Based on aggregated 13F filings for Q3 2016.